Skip to main content

Safety and Effectiveness of the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation

Active, not recruiting · Not applicable · NCT05462145

Conditions: Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation

At a glance

Research payments reported, 2025
$215,118
U.S. investigators named
9
Sites paid
10
Planned or actual enrollment
549

About the trial

Sponsor
Kardium Inc.
Tested
Globe Pulsed Field System (device)
Dates
Started 2023-03-09; completion 2029-03
Results posted
Not yet

This study will evaluate the safety and effectiveness of the Globe® Pulsed Field System for treating patients with symptomatic paroxysmal or persistent atrial fibrillation (AF).

From ClinicalTrials.gov, last updated 2026-10-06. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Kardium Inc. reported $215,118 in research payments for this study in 2025 (482 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Sutter Bay Hospitals $87,470
  • St. Vincent's Health System, Inc. D/b/a Ascension St. Vincent's $49,523
  • The Johns Hopkins University $31,279
  • Arrhythmia Research Group $15,826
  • The Cleveland Clinic Foundation $11,808
  • William Beaumont Hospital $5,000
  • The University of Alabama at Birmingham $4,500
  • HCA Florida Mercy Hospital $4,462
  • Doylestown Hospital $3,750
  • Affinity Hospital, LLC D/b/a Grandview Medical Center $1,500

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.